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Abstract
Background: There is a need for a new cardiovascular disease model that includes a wider range
of relevant risk factors, in particular lifestyle factors, to aid targeting of interventions and improve
population models of the impact of cardiovascular disease and preventive strategies. The model
needs to be applicable to a wider population including different ethnic groups, different countries
and to those with and without cardiovascular disease. This paper describes the construction of the
Cardiovascular Health Improvement Model that aims to meet these requirements.
Method: An odds model is used. Information was taken from 2003 mortality statistics for England
and Wales, the Health Survey for England 2003 and published data on relative risk in those with
and without CVD and mean blood pressure values in hypertensives. The odds ratios used were
taken from the INTERHEART study.
Results: A worked example is given calculating the 10-year coronary heart disease risk for a 57
year-old non-diabetic male with no personal or family history of cardiovascular disease, who
smokes 30 cigarettes a day and has a systolic blood pressure of 137 mmHg, a total cholesterol (TC)
of 6.2 mmol/l, a high density lipoprotein (HDL) of 1.3 mol/l, and a body mass index of 21. He neither
drinks regularly nor exercises. He can give no reliable information about his mental health or fruit
and vegetable intake. His 10-year risk of CHD death is 2.47%.
Conclusion: This paper demonstrates a method for developing a CHD risk model. Further
improvements could be made to the model with additional information. The method is applicable
to other causes of death.
1 Background
There are several reasons for calculating the risk of cardio-
vascular disease in an individual or a population. Health
care providers need to model future patterns of need for
health services, and to identify the cost effectiveness of dif-
ferent intervention strategies.[1,2] Insurance companies
and pension funds must evaluate risk in both individuals
and populations when assessing portfolio risks. In clinical
medicine, cardiovascular risk is increasingly accepted as
the appropriate criterion to use to identify those who will
most benefit from interventions designed to prevent car-
diovascular disease and death.[3,4] Another, perhaps
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overlooked requirement, is to inform shared decision-
making with patients.[5]
This paper describes a cardiovascular disease (CVD)
model which has been developed specifically for use in
consultations with patients as an aid to risk communica-
tion and to shared decision making. Most CVD models
focus on coronary heart disease (CHD) events, such as
myocardial infarction. However, it is sometimes difficult
to categorize an individual as either having or not having
experienced a CHD event, since the collection of data on
such events varies according to methods and definitions
used. Consequently, an evaluation of all CHD or CVD
events will be less reliable than one with a more concrete
outcome measure such as CHD and CVD death.[6] The
model we propose therefore estimates death from CHD.
There are a variety of CVD risk estimators available, the
best known are summarized in Table 1. Each has strengths
and weaknesses. [6-12] The principal problems include
limited applicability to different geographic areas or eth-
nic groups, application to men but not women, and the
omission of important risk factors.[13,14]
The best known estimators are the Framingham equa-
tions. These have been criticized for their inaccuracy in
some countries, in particular Southern Europe where they
tend to over-estimate risk significantly.[14] This variation
is an inevitable consequence of the exclusion of signifi-
cant risk factors from the model. If a model is derived in a
particular population, the prevalence and impact of any
missing risk factors is tacitly embedded in coefficients of
the risk equations. When applied to a population with dif-
ferent prevalences or one in which risk factors have differ-
ent impacts, the model's predictions will be less accurate.
Attempts have been made to recalibrate the Framingham
equations for different ethnic groups in the United States
and the United Kingdom. [11,15] However, the recali-
brated equations have not been validated and questions
about their applicability to other geographic areas remain
unanswered.
The models in Table 1 all include age, gender, blood pres-
sure, cholesterol, cigarette consumption and diabetes as
risk factors. All omit some important independent risk
factors such as family history, existing CVD, obesity but
also diet, alcohol consumption and exercise. We are par-
ticularly interested in risk factors related to lifestyle: if an
Table 1: Major cardiovascular risk models and their inputs and outputs.
Risk equation Risk factors included Risks evaluated
Framingham (Anderson)[7] Age, gender, smoking, blood pressure (BP), 
total cholesterol (TC)/high density lipoprotein 
(HDL) ratio, diabetes, left ventricular 
hypertrophy (LVH)
4 to 12-year risk of CHD events and death, all 
CVD events and death, all cerebrovascular 
events, myocardial infarction events.
Framingham (D'Agostino)[12] Age, gender, smoking, BP, TC/HDL ratio, 
alcohol, existing CVD, menopausal status 
(women), triglycerides in women
2-year risk of CHD events.
Whitehall equation[32] Age, gender, TC, BP, cigarettes per day 5 or 10-year risk of CHD event.
Systematic Coronary Risk Evaluation 
(SCORE)[6]
Age, gender, smoking, BP, TC and residence in 
a 'high' or 'low' risk country.
10-year risk of death from CHD or CVD.
Munster Heart Study (PROCAM)[33] Age, smoking, BP, low density lipoprotein 
(LDL), HDL, triglycerides, gamma glutamyl 
transferase (γGT), diabetes, existing angina, 
family history
Major coronary event.
Ethrisk[11] Age, gender, smoking, BP, TC/HDL ratio, 
diabetes, LVH and ethnic group
10-year risk of CHD event.
ASSIGN[10] Age, gender, cigarettes per day, systolic BP, 
TC/HDL ratio, family history, SIMDSC10 
deprivation score
10-year risk of CVD.
QRisk[9] Age, gender, smoking, BP, TC/HDL, body mass 
index (BMI), family history, treatment with 
antihypertensive drugs, Townsend area 
deprivation score.
10-year risk of CVD events.BMC Medical Informatics and Decision Making 2008, 8:49 http://www.biomedcentral.com/1472-6947/8/49
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estimate of risk is to be used in consultations as part of
discussions with patients about lifestyle modification, it is
important that the estimate should include the fullest pos-
sible range of risk factors relating to lifestyle.
To improve CVD risk equations, it is necessary both to
expand the number of risk factors used and to devise a
method of calibrating the results to different populations.
Including additional risk factors should improve the accu-
racy at the level of the individual and increase the porta-
bility of any risk equation to different populations,
however, there will always be some residual variability
not accounted for by included risk factors. National mor-
tality statistics can be regarded as containing all possible
information about risk, both known and unknown. Rec-
alibrating such national mortality statistics according to
the mean values for a broad set of known risk factors will
leave a residual value for the remaining variability due to
unknown factors. The 2003 Health Survey for England
collected information on cardiovascular disease risk fac-
tors and prevalence which can be used to recalibrate
national mortality statistics in this way.[16,17]
This paper describes how to take publicly available infor-
mation on CHD prevalence, CHD death rates and CHD
risk factors, and use it to calculate the risk of coronary
heart disease for individuals, using an approach that
should be applicable in different geographical areas and
different ethnic groups.
2 Method
In this section, we first explain the mathematics underly-
ing our approach and then describe how the data items
required by the model were obtained. The approach uses
an odds model. The odds of dying of cardiovascular dis-
ease in time t are:
where Pt is the probability of dying of cardiovascular dis-
ease in time t.
If we know the average odds of death in time t for the
given population (PopOt), we can calculate an odds ratio
adjustment for any individual based on known risk fac-
tors, and use it to estimate the odds for the individual as:
IndOt = PopOt.IndOR
The odds ratio for the individual (IndOR) is the product
of the odds ratios for each of n risk factors:
This is often expressed as:
IndOR = eλ
where λ is the sum of terms corresponding to each risk fac-
tor, each term consisting of a coefficient β – a measure of
the contribution of the risk factor – adjusted according to
the extent to which the risk factor is present in an individ-
ual compared to the average for the population in ques-
tion. Thus:
where βi is the coefficient associated with the ith risk factor
(equal to the log of the odds ratio), si is the value for the
individual of the risk factor and   is the average popula-
tion level. This is a well established method of adjusting
models to different populations, used in SCORE and
ETHRISK.[11,18,19]
In logistic regression, βi are constants representing a linear
relationship between the log odds and the level of the risk
factor. This approach can be applied whether the risk fac-
tor, si, is a continuous, categorical or a binary variable.
However, in the literature, continuous risk factors are fre-
quently treated as categorical variables: for example, a
study might give odds ratios for each quintile of waist-to-
hip ratio (using the first quintile as the reference cate-
gory). While these values could be used directly, that
would produce artefacts in the model near quintile
boundaries, so it is sensible to convert back to a continu-
ous variable by applying smoothing. However, with some
risk factors, the resultant relationship is not linear. Our
approach here is to calculate an interpolated and
smoothed function for how the odds ratio varies with si
(which is equivalent to considering βi not as a constant
but as a function of si). In these cases, instead of calculat-
ing a term
we calculate a term:
O
Pt
Pt
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which is the log of the odds ratio for the individual for the
ith risk factor (i.e. associated with the measured value si),
divided by the odds ratio for the mean level in the popu-
lation of the same risk factor (i.e. associated with  ).
These terms are referred to as the log of the normalized
odds ratio (LNOR) and are represented by ξi. So our λ is
calculated as:
The model therefore requires:
￿ estimates of the baseline mortality from CHD (PopOt);
￿ a set of risk factors with known odds ratios;
￿ LNORs for each risk factor.
In the following three subsections of the paper we explain
(1) how estimates were derived for baseline CHD mortal-
ity, (2) choice of a set of risk factors, and (3) how adjusted
LNORs were determined for each risk factor. We then go
through a worked example for an individual patient.
2.1 Baseline Mortality
The mortality of CHD was extracted from the UK national
mortality statistics 2003.[20] The ICD-10 codes included
for CHD were I20–I25 inclusive. A probability of death
from CHD for each age band was calculated for each gen-
der by dividing the number of deaths in the age band by
the number of individuals in the population in that age
band. The annual death rates for each age from 35 years-
old upwards were then smoothly interpolated using
methods described below. The probability of death was
set to zero below the age of 35 as the death rates in this
group were negligible.
National mortality statistics include all CHD deaths in the
population. This includes CHD death in those with pre-
existing CVD as well as those who were free of CVD. If we
know the proportion of the population who had pre-exist-
ing CVD, the number of CHD deaths and the relative risk
of CHD in those with CVD as compared to those without,
then separate estimates can be made of the baseline CHD
mortality in the two groups. If:
M = Mortality from CHD for that age and gender.
M1 = Mortality from CHD in individuals without prior
CVD.
M2 = Mortality from CHD in individuals with prior CVD.
Pr = Prevalence of CVD for that age and gender.
and RR = the relative risk of CHD in those with a prior his-
tory of CVD compared to those without.
Then:
M = M1.(1 - Pr) + M2.Pr
Since
M2 = M1.RR
we have
M = M1.(1 - Pr) + M1.RR.Pr
Thus:
We calculate baseline estimates of CHD mortality for an
individual with given age, gender and CVD status. M is
then calculated from national mortality statistics and PR
from the Health Survey for England 2003, interpolated
using the approach described below. A figure of 3.3 was
used for the RR for CHD death or sudden death in those
with existing CHD, taken from the Framingham study.
[21]
2.1.1 Smooth interpolation of mortality and prevalence rates
The prevalence rates for CVD are given in the Health Sur-
vey for England 2003 in 10-year age bands. The mortality
statistics are given in 5-year age bands. To obtain accurate
annual estimates of baseline mortality rates it is necessary
to interpolate from these totals. A number of different
methods were explored, including simple linear, cubic
spline and fractional polynomials, but all proved unsatis-
factory.[22,23]
Linear interpolation using the mid points of the 5-year age
bands fails to preserve the area under the curve within the
age bands where there is a high rate of change of risk. Also,
the effect of the sharp changes in risk at the the mid-point
inflections is magnified in subsequent calculations to give
artefactual 'edge effects'.
Interpolating with a spline function would generate a pol-
ynomial for each age band, requiring thirty or forty coeffi-
cients to describe a mortality curve from age fifteen to
ninety. In addition, ensuring that the average value
matches the average value for the age band, can result in
values below zero at very low risks. Fractional polynomi-
als can be fitted for narrow intervals, but as the polyno-
si
λξ =
=
= ∑ i i
in
1
(3)
M
M
RR
1 1
=
−+ () Pr .Pr
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mial functions may tend towards plus or minus infinity, it
is difficult to fit one fractional polynomial over the wide
age ranges needed without experiencing what is called
Runge's phenomenon, where the included data points are
fitted very well, but with dramatic error between them.
[24]
A key problem is that the area under the cumulative mor-
tality curve needs to be conserved. A two-step process was
developed in which a smoothing algorithm generates a
curve which is then modeled as a weighted sum of sixteen
Normal distribution curves.
An interpolated curve is first generated by redistributing
the area under the stepped curve obtained from the initial
data: the sharpest angle in each age band is identified, by
finding the biggest change in angle and dividing it by the
absolute value of y-axis point. That data point is shifted
towards the further of the two adjacent data points. The
amount by which the data point is increased or decreased
is then redistributed to the other data points in the age
band. The process is repeated, iteratively reducing the
maximum angle and resulting in a smooth curve that does
not fall below zero, and preserves the area under the curve
in each age band.
Below the age of 35, the prevalence and mortality are set
to zero. For ages 35 and above, a function of a set of nor-
mal distribution curves was generated from the points in
the smoothed curve. This produces a more tractable equa-
tion. Generating all data points prior to finding the best fit
function prevents Runge's phenomenon. The parameters
and weightings – determined by the least squares method
– of the Normal distributions are shown in Table 2. Figure
1 shows the result of the interpolation of coronary heart
disease results against the original stepwise mortality for
Table 2: The coefficients for the normal distribution curves for mortality and prevalence functions.
Normal distribution
(μ, δ)
Male CVD Prevalence Female CVD Prevalence Male CHD mortality Female CHD mortality
Constant -4.46924 -3.7276 0.028432 -0.06621
(20,5) -1.66148 -1.40524 0.027838 -0.07657
(30,5) 2.566571 2.165315 0.02106 0.003326
(40,5) 3.595888 3.149946 0.020598 0.007303
(50,5) 4.457566 3.667629 0.019311 0.000279
(60,5) 6.476155 5.555759 0.011118 -0.00443
(70,5) 11.12182 8.868936 0.021131 -0.00807
(80,5) 10.75465 9.161873 0.015343 -0.00909
(90,5) -2.37347 -2.19787 -0.03721 -0.03203
(25,10) -37.9802 -31.3032 0.223831 -0.74789
(45,10) 4.541968 6.42029 0.193671 -0.03395
(65,10) 10.22757 12.67255 0.026298 -0.18066
(85,10) 21.14716 23.89516 0.160345 -0.36785
(20,15) 204.0157 170.2051 -1.38416 3.377389
(50,15) 42.36992 30.87008 -1.85748 0.545179
(80,15) -91.5426 -90.6798 -2.89911 -0.95328
(90,30) 429.1505 365.718 5.065048 8.756594BMC Medical Informatics and Decision Making 2008, 8:49 http://www.biomedcentral.com/1472-6947/8/49
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the five-year age bands. This curve can be generated using
no more than 16 numbers, does not violate the normal
bounds of probability, is not affected by Runge;s phenom-
enon, and preserves the total risk in each age band.
2.2 Risk factors
The most comprehensive data on the odds ratios associ-
ated with a set of risk factors has come from the INTER-
HEART study, which collected data from 15,152 patients
admitted for a first MI at 262 centres in 52 countries across
the world, and 14,820 matched controls. [25] The INTER-
HEART study identified nine risk factors in addition to age
and gender, which accounted for 90% of population
attributable risk (PAR) in men and 94% in women for first
myocardial infarction. We assume that the odds ratios for
the risk of MI will be very similar to the odds ratios for
CHD in general. The nine risk factors identified in addi-
tion to age and gender were: smoking status, a diagnosis
of hypertension, apolipoprotein B/apolipoprotein A1
ratio, diabetes mellitus, waist/hip circumference ratio,
alcohol consumption, consumption of fresh fruit and veg-
etables, exercise and psychosocial stress. A tenth factor, a
family history of CHD, is also given in the paper but was
omitted from the list of nine as it had minimal impact on
the PAR. It has been included here as it enhances the indi-
vidualization of the calculation regardless of the overall
impact on the calculated population mortality.
The nine risk factors identified in the INTERHEART study
are shown in Table 3 along with the unadjusted odds
ratios.
2.3 Estimating the adjustments for each risk factor
We use an odds model in which the impact of risk factors
on an individual's risk for CHD death is determined as the
product of a set of coefficients, one for each risk factor.
The coefficients (the log of the normalized odds ratios,
LNOR) provide a measure of the influence of the meas-
ured risk factor for that individual.
The population mean values were derived from the
Health Survey for England 2003 for different gender and
age groups, with the values interpolated using polynomi-
als; details are given in tables 4. The following subsections
detail the calculations of the LNORs for each of the risk
factors used.
showing the resulting curve generated for the risk of death from coronary heart disease in men compared to the original step- wise 5-year age band mortality Figure 1
showing the resulting curve generated for the risk of death from coronary heart disease in men compared to 
the original stepwise 5-year age band mortality.BMC Medical Informatics and Decision Making 2008, 8:49 http://www.biomedcentral.com/1472-6947/8/49
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2.3.1 ApoB/ApoA1 ratio
Total cholesterol (TC) and high density lipoprotein
(HDL) values are the most common measures of lipid
level used in calculating CVD risk. However, the INTER-
HEART study found that using the ratio of apolipoprotein
B (ApoB) and apolipoprotein A1 (ApoA1) is a more sen-
sitive measure of risk than the TC/HDL ratio.
The INTERHEART study explored the relationship
between the deciles of ApoB/A1 ratio and the odds ratio
for MI compared to the first decile. The relationship is
plotted on a doubling scale in the original paper, but it
would appear that the relationship between the odds ratio
and the ApoB/A1 ratio is linear from the second decile
upwards, but with the odds ratio having a floor of 1 from
just below the second decile. This can be seen in Figure 2.
Linear regression gives the equation:
where x is the ApoB/ApoA1 ratio.
The LNOR ξi for ApoB/A1 ratio is the log of the of the nor-
malized odds ratio for an individual's ApoB/A1 ratio (Ind-
ORApo) divided by the odds ratio for the population
average (PopORApo) calculated from the above equation.
From equation (2), LNOR ξApo coefficient is then:
The ApoB/A1 ratio is often not known as it is more cus-
tomary to use TC/HDL clinically. An approximate conver-
sion factor is applied: [26]
2.3.2 Smoking
The relationship between the odds ratio for first MI and
smoking and cigarette consumption with respect to non-
smokers appears non-linear in the original INTERHEART
paper.[25] However, as can be seen from Figure 3, if it is
assumed that the odds ratio for 20 cigarettes a day is an
outlier – there may have been some rounding down in the
cigarette consumption to the standard packet size of 20 by
either the subjects or observers – then this too is a linear
relationship. Linear regression gives an equation:
ORcig = 1 + 0.153145 × N (7)
where N is the daily cigarette consumption.
To calculate the odds ratio corrected for the population,
the interim odds for the population average cigarette con-
sumption needs to be calculated. The population average
cigarette consumption is the cigarette consumption for
the whole population, not just smokers. This can be calcu-
lated:
Av. cigarette consumption = av. consumption for smokers 
× proportion that are smokers
The LNOR is then:
OR
xi f x
if x
=
−+ >
≤
⎧
⎨
⎩
17 52 3 05
10 5
.. . .
.
 
 
(5)
ξApo
IndORApo
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=
⎛
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⎜
⎞
⎠
⎟
⎟
ln
ApoB/A1 ratio 
(TC/HDL
=
)
. 44 1
(6)
Table 3: The risk factors identified in the INTERHEART study, their definitions and odds ratios.
Risk factor Definition OR
Smoking status[25] Current versus non-smoker 2.87
ApoB/ApoA1 ratio (personal communication)
2nd versus 1st quintile <0.57 1.42
3rd versus 1st quintile 0.57–0.69 1.84
4th versus 1st quintile 0.69–0.82 2.41
5th versus 1st quintile 0.98 3.25
History of hypertension[25] Self reported 1.91
Diabetes mellitus[25] Self reported 2.37
Abdominal obesity[29] Waist to hip ratio
2nd versus 1st quintile Women: 0.79–0.84, men: 0.87–0.91 1.03
3rd versus 1st quintile Women: 0.84–0.89, men: 0.91–0.94 1.083
4th versus 1st quintile Women: 0.89–0.94, men: 0.94–0.98 1.379
5th versus 1st quintile Women: 0.94->, men: 0.98-> 1.666
Psychosocial factors[25] An unreported algorithm 2.67
Family history of premature CVD A first degree relative <55 for men and <60 for women 1.45
Consumption of fruit and vegetables[25] Daily consumption versus not 0.70
Regular alcohol consumption[25] At least three days a week 0.91
Regular physical activity[25] At least four hours a week 0.86BMC Medical Informatics and Decision Making 2008, 8:49 http://www.biomedcentral.com/1472-6947/8/49
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2.3.3 Systolic blood pressure
The odds ratios given in the INTERHEART study are for
self reported hypertension only. We can make an estimate
of the odds ratio by systolic blood pressure versus the
average systolic in a non-hypertensive if we assume that
the odds are proportional to changes in the systolic blood
pressure, and if we know the average values for the hyper-
tensive and non-hypertensive groups. This information
was not available to us, so an estimate needed to be made
from another source. The average systolic in the ASCOT
study was 164 mmHg, which was also the value in a study
of home monitoring of Danish hypertensives.[27,28] This
seems to be a reasonable estimate for the hypertensive
group. Estimating the average value in the non-hyperten-
sive group is more difficult, as this is highly dependent on
age and gender. However, a value of 130 mmHg was used
as this would be a typical value in the 35 to 64 year old age
group in the Health Survey for England.[16]
If we assume that the OR for a hypertensive with a systolic
of 164 mmHg is 1.91 (table 3), then the gradient of the
function relating the odds ratio to the systolic BP can be
calculated as:
Then using the intercept -2.4794 derived from the INTER-
HEART data we can use the equation to determine the
odds ratio for systolic blood pressure with reference to the
average normal systolic blood pressure of 130 mmHg:
ORSyst = -2.4794 + 0.0268 × Systolic (9)
Armed with the gradient of the line and the intercept, we
can calculate the odds ratio for any systolic blood pressure
with reference to the assumed normal value of 130
mmHg. The individual odds ratio, IndORSyst is calculated
using the individual systolic blood pressure, and the pop-
ulation odds ratio PopORSyst is calculated using the aver-
age systolic blood pressure for that age. The LNOR ξ for
systolic blood pressure can then be calculated using equa-
tion (2).
2.3.4 Obesity
The INTERHEART study found that waist-hip circumfer-
ence ratio (WHR) was a better measure of the contribu-
tion of obesity to the risk of first myocardial infarction
than body mass index (BMI). However, since data is more
readily available for BMI than WHR, a conversion func-
tion from BMI to WHR was derived. The function used to
ξCig
IORCig
PORCig
=
⎛
⎝
⎜
⎜
⎞
⎠
⎟
⎟
ln
()
()
(. )
()
.
OR
HS NHS
per mmHg
−
−
=
−
−
=
11 9 1 1
164 130
0 0268    
(8)
showing the relationship between the odds ratio for first MI and deciles of ApoB/A1 ratio with respect to the first decile Figure 2
showing the relationship between the odds ratio for first MI and deciles of ApoB/A1 ratio with respect to the 
first decile.BMC Medical Informatics and Decision Making 2008, 8:49 http://www.biomedcentral.com/1472-6947/8/49
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estimate waist hip ratio from the BMI and age was derived
by linear regression using data from the Health Survey for
England:
For men:
WHR = 0.409665 + 0.000945*Age + 0.017275*BMI
(10)
For women:
WHR = 0.714408 + 0.001312*Age + 0.001546*BMI
(11)
The INTERHEART team published odds ratios for each of
the upper four quintiles of WHR compared to the low-
est.[29] The odds ratio is not a linear function of the
WHR, so a fractional polynomial was fitted to interpolate
the data with reference to the mean WHR of the lowest
quintile (Tables 4). The odds ratio for the individual (IOR-
WHR) and the population (PORWHR) can then be calculated
to give the LNOR:
2.3.5 All other risk factors
All the other risk factors are binary. The beta coefficients
are taken as the simple log of the odds, and the adjusted
proportion is the value for the individual (1 or 0) minus
the proportion affected in the population. So for a 60 year
old male diabetic:
ξDM = ln(OR for diabetics)*(individual value - population 
prevalence)
ξDM = ln(2.37)*(1 - 0.081) = 0.793
2.4 Implementation
The model was implemented first in Matlab and then in
Microsoft Excel to ensure freedom for errors.
3 Results
Here we will describe a worked example. We will find the
10-year coronary heart disease risk for a 57 year-old non-
diabetic male who smokes 30 cigarettes a day with no per-
sonal but a positive family history of cardiovascular dis-
ease, a systolic blood pressure of 137 mmHg, a total
cholesterol (TC) of 6.2 mmol/l, a high density lipoprotein
(HDL) of 1.3 mol/l, and a body mass index of 21. He nei-
ther drinks regularly nor exercises. He can give no reliable ξWHR
IORWHR
PORWHR
=
⎛
⎝
⎜
⎞
⎠
⎟ ln
showing the relationship between the odds ratio for first MI and cigarette consumption with respect to non-smoking Figure 3
showing the relationship between the odds ratio for first MI and cigarette consumption with respect to non-
smoking.BMC Medical Informatics and Decision Making 2008, 8:49 http://www.biomedcentral.com/1472-6947/8/49
Page 10 of 15
(page number not for citation purposes)
information about his mental health or fruit and vegeta-
ble intake.
3.1 ApoB/ApoA1 ratio
The ratio is not known in this case, so must be estimated
from the TC/HDL ratio using equation (6).
ApoB/A1I ≈ TC/HDL/4.41 = (6.2/1.3)/4.41 = 1.0856
The population average ApoB/ApoA1 ratio (BARP) can be
estimated from values for the age and gender-adjusted
estimates of TC and HDL using the coefficients in Addi-
tional file 1, thus:
PopTC = 23.8522 - 0.234959 * Age + 0.00093059 * Age2 - 
510.144 * Age-1 + 4193.01 * Age-2 = 5.82
PopHDL = 1.4 (constant with age)
PopApoB/A1 ≈ 5.82/1.4/4.41 = 0.9433
The log odds ratio for the individual (ORI) is calculated
from equations (5) and (2):
3.2 Smoking
The average cigarette consumption in the population for
this age and gender is calculated using the coefficients
fond in the table in Additional file 1. The product of this
and the proportion of smokers for any given age is the
population average cigarette consumption. In this case:
NCig = 132944 + 53126.53*Age + 31.019*Age2 - 
0.043639*Age3 - 238356*Age1/2 + 121635.8*ln(Age) - 
8444.51*Age.ln(Age) = 16.3
The proportion of smokers at this age is:
S = -4.253823986 + 0.059180468 * Age - 0.00031514 * 
Age2 + 149.8257235 * Age-1 - 1666.023544 * Age-2 = 
0.2113
Therefore the average number of cigarettes smoked by the
population is:
NCig = 0.2113 * 16.3 = 3.4
Using equation (7) the odds ratio (PopOR) is thus:
PORCig = 1 + NCig * 0.153145 = 1.5207
The odds ratio (OR) for the individual is calculated in the
same way.
IORCig = 1 + 30 * 0.153145 = 5.59
And the ξSmok using equation (2) is
3.3 Systolic blood pressure
The population average systolic pressure using the coeffi-
cients in Additional file 1 is:
PopSys = -23.669 + 2.43064*Age + -0.010641*Age2 + 
3674*Age-1 + -32482*Age-2 = 129 mmHg
The reference group for the odds ratios is systolics at or
below 115 mmHg, otherwise it is calculated from gradient
and intercept as determined in section 2.3.3: (equation 9)
3.4 Waist hip ratio
The WHR is estimated from the age and the BMI using the
equation (10):
WHR = 0.409665 + 0.000945*Age + 0.017275*BMI = 
0.8310
The population average for WHR (PopWHR) for a man of
his age is:
PopWHR = 0.7193 + 0.0071729*Age - 0.0000536*Age2 = 
0.9544
The odds ratio for this individual for the calculated WHR
using the coefficients in the Additional file 1 is:
IndORWHR = -41246.21 + 29780.1318*WHR - 
8043.6837*WHR2 + 25335.086*(1/WHR) - 
823.58436*(1/WHR2) = 0.8310
As this is less than 1.0, the individual WHR is taken as 1.
And for the population average WHR is:
PopORWHR = 1.3207 using the same formula.
The LNOR ξ for WHR using equation (2) is thus:
3.5 Diabetes mellitus
The baseline probability of having diabetes at this age
(PopDM) using the coefficients in the Additional file 1 is:
ξBA = ⎛
⎝
⎜
⎞
⎠
⎟ = ln .
-1.7+5.23*1.0856
-1.7+5.23*0.9433
0 2073
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PopDM = -2.80714 + 0.047436*Age + -0.00025594*Age2 
+ 67.419*Age-1 + -562.65*Age-2
PopDM = 0.07476
And the LNOR ξ using equation (1) is:
ξDM = ln(2.37)*(0-0.07476) = -0.0645
3.6 Regular alcohol consumption
The baseline probability of being a regular alcohol drinker
at this age (PAlc) using the coefficients in the Additional
file 1 is:
PAlc = -3.82669 + 0.076117*Age + -0.000462694*Age2 + 
100*Age-1 + -889.34*Age-2 = 0.4323
And the LNOR ξAlc using equation (1) is:
ξAlc = ln(0.91).(0 - 0.4323) = -0.0535
3.7 Psychosocial stress and fruit and vegetable 
consumption
There is no information available for either of these risk
factors, and so an assumption is made that the individual
is exactly average for the population. As that means the
difference between the individual risk factor value and the
mean population value is zero, the LNOR will be zero.
3.8 Exercise
The population proportion of exercisers at this age (PEx)
using the coefficients in the Additional file 1 is:
PEx = 2.3532 + -0.0205299*Age + 3.23113.10-6.*Age2 - 
60.944*Age-1 + 653.57.*Age-2
PEx = 0.32542
And the LNOR ξEx using equation (1) is:
ξEx = ln(0.86).(0 - 0.32542) = 0.0491
3.9 Family history of CVD
The baseline probability of having a family history of CVD
at this age (PFH) is calculated from the prevalence of CVD
in men at age 57 (CVD42):
FHCVD = 1 - (1-CVD42)2 = 0.24
And the LNOR ξFH using equation (1) is:
ξFH = ln(1.45)*(0-0.24) = -0.0892
Calculating mortality
The 10 year mortality rate BM10 can be calculated as:
The baseline mortality odds (BMO) is therefore:
and the baseline mortality at a given age i (BMi) is found
using the set of Normal distribution curves with the
means and standard deviations in set A:
A = {(20 5), (30-5), (40-5), (50-5), (60-5), (70-5), (80-5), 
(90-5), (25-10), (45-10), (65-10), (85-10), (20 15), (50 
15), (80 15), (90 30)}
And the following set of coefficients C from the Table 2,
the first of which is a constant:
C = {0.028432143 0.02783794 0.021060258 
0.020598088 0.019311202 0.011118031 0.021130765 
0.015343166 -0.037214697 0.223830756 0.193671366 
0.026298386 0.160344847 -1.384157929 -1.857484078 
-2.899112366 5.065048492}
BM10 = 0.0024886
The prevalence of CHD is calculated in a similar manner
using the coefficients in the Table 2 to give:
BM0 = 0.00493/(1-0.00493) = 0.0025
PrCHD = 0.01483
We can then correct the mortality for the presence or
absence of CVD, using equation:
Converting this probability to odds, the value remains at
0.0048.
We then calculate the λ as the sum of all the LNORs using
equation (3):
λ = 1.2979 - 0.0645 + 0.0463 + 0.2073 + 0.0491 - 0.2781 
+ 0.2824 + 0.0514 = 0.2973
Our adjusted odds for death are thus:
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Odds for death in 10 years from CHD = eλ*0.2973 = 0.0254
This is then converted back from odds to probabilities:
The 10-year probability of death from CHD = 0.0254/
(1+0.0254) = 0.0247 = 2.47%
4 Discussion
This exercise demonstrates how published information
can be used to construct a mathematical model of cardio-
vascular risk. The same methods should be applicable to
other disease groups where there is sufficient information
available. The method requires: the odds ratios for each of
the risk factors when controlled for all other risk factors;
mortality rates and prevalences for the diseases of interest;
and prevalence rates and mean values for the risk factors
in the relevant population.
Before use, this model must be tested in different popula-
tions to assess its accuracy. The results of the INTER-
HEART study would suggest that it should be applicable
in different geographical locations and to different ethnic
groups without adjustment, since the predictions are
anchored in a dataset for which there is a great deal of
information on mortality rates and mean values. The
INTERHEART study would suggest the residual variation
at a population level is significantly less than ten percent.
However, it should still be possible to apply the same
principles by substituting the mortality data and the prev-
alence data for any population where that information is
available to improve accuracy.
A major advantage of this model is the comprehensive set
of independent risk factors used. It is likely that other risk
factors have very little residual independence once all
these factors are taken into account. For example, social
and economic deprivation is included in other CVD and
CHD models such as QRisk and Assign.[9,10] The INTER-
HEART study was conducted in 52 countries including
low and middle income countries, and yet this factor did
not emerge as significant when all nine risk factors were
included. Equally, country and ethnicity did not remain as
independent risk factors suggesting that the odds ratios
derived are applicable in all 52 countries. It would seem
plausible that the odds ratios are also applicable in coun-
tries not included in this study.
4.1 Limitations
4.1.1 Assumptions
A large number of assumptions were made in the con-
struction of this model. The more important assumptions
that might limit the accuracy of the model are described
below.
4.1.1.1 That the underlying pathological processes and aetiological 
factors are the same for atheromatous disease, whether it is 
myocardial infarction, cerebrovascular or angina pectoris. This 
excludes death from haemorrhagic stroke
The odds ratios for the different cardiovascular patholo-
gies should be highly correlated because there is a com-
mon underlying process at work, the formation of
atheroma. However, there may be variations that are spe-
cific to certain pathologies, such as atrial fibrillation and
stroke. In the INTERHEART study the subjects had experi-
enced a first MI. Factors such as blood viscosity have a
greater impact on MI than chronic ischaemia. It is possible
that some of the modeled risk factors – such as psychoso-
cial stress – may affect MI and chronic ischaemia, in dif-
ferent ways.
We assume that the risk factor profiles and odds ratios for
those risk factors are similar in those who die from an MI
before reaching hospital and those who survive. In a cross-
sectional study like INTERHEART, the outomes are not
entirely equivalent to the prospective predictions of death
from MI or CHD. In the INTERHEART study, subjects
were identified on presentation with a first MI. Many
potential subjects will have not survived to be recruited
into the study. If there are significant differences between
those that survive to hospital and those that don't, then
some error will be generated in this model.
4.1.1.2 That the odds ratios for each risk factor are the same for 
those with and without CVD
We assume that the pathological processes affecting pro-
gression of asymptomatic, mild atheroma to sympto-
matic, moderate atheroma, are essentially the same as
those causing further progression of existing moderate
atheroma, and that the scale of effect of the different risk
factors is the same at all stages of disease. This is not nec-
essarily true, different risk factors might have particular
significance at difference stages of disease. For example it
is possible that some risk factors have a particular role in
plaque rupture, or thrombus formation, and less in
plaque formation.
4.1.1.3 That the odds ratios apply equally to all populations 
regardless of geography, ethnicity or socioeconomic group
The INTERHEART study found that, once all nine final
risk factors were included, country, and ethnicity and soci-
oeconomic group did not have a significant effect. The
well recognized ethnic, geographic and socioeconomic
differences on CVD must therefore be mediated by the
included risk factors. To apply the odds ratios to a given
population, what we require, is the mortality rate in that
population and the average value for all the included risk
factors in that population at that time. We have used the
mortality of CHD in the UK in 2003, and the average val-
ues for the risk factors used, in the UK in 2003. These willBMC Medical Informatics and Decision Making 2008, 8:49 http://www.biomedcentral.com/1472-6947/8/49
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differ from the mortality and average risk factor values in
the INTERHEART study. However, if this result of the
INTERHEART study, that the odds ratios apply regardless
of geography and ethnicity, is robust then this should not
affect the results.
4.1.1.4 That hypertensives had an average systolic of 164 mmHg 
and non-hypertensives had an average systolic of 130 mmg in the 
INTERHEART study and the relationship between the odds ratio and 
systolic blood pressure is linear
With regard to the systolic values for hypertensives and
non-hypertensives, this is very uncertain whether this
assumption is accurate, but is based on data from two dif-
ferent countries, and would seem to be reasonable
assumptions in the absence of better information. Data
on the precise values in the INTERHEART study would
possibly improve the model and increase confidence in it.
The systolic blood pressure was modeled here with an
assumption of a linear relationship with the odds ratio.
However, the results in Lewington et al 2002 would sug-
gest that the age-adjusted absolute risk varies on a dou-
bling scale with systolic blood pressure [30] and, previous
work would suggest that this linear relationship does not
hold for very severe hypertensives.[31] The INTERHEART
study was unable to determine the relationship between
the systolic and odds ratio adjusted for all nine risk factors
and so we felt an assumption of a linear relationship was
reasonable.
4.1.1.5 That the relative risk for coronary heart disease death in 
those with pre-existing CVD is 3.3, regardless of the type of pre-
existing CVD
This is a weak assumption, and based on a figure after
Kannel.[21] Different types of existing cardiovascular dis-
ease will have different degrees of impact on risk.[31] The
figure found by Kannel may be an average of these differ-
ing values. The value of this assumption will need to be
tested in an evaluation of the model on external data.
4.1.1.6 That the odds ratios for the different risk factors remain 
constant over time and at different ages
The odds ratios given in the INTERHEART study relate to
the occurrence of first MI, and the risk factor data was col-
lected at that time. It is unclear how those odds ratios dif-
fer over time and with the age of subjects. Also, older
subjects will have higher risks of competing causes of
death, and this may in turn affect the odds ratios for the
risk factors predicting CVD.
4.1.1.7 Other limitations
Using a wider range of risk factors can reduce the accuracy
of the model if the available data on the additional risk
factors is poor. Models developed using fewer risk factors
embed information pertinent to the missing risk factors
within the regression coefficients for factors that interact
with the missing risk factors. With the larger models, the
coefficients will have been regressed in the presence of
those risk factors and so if that information is missing –
for example if patients' fruit and vegetable consumption is
not recorded in a dataset – their effect is lost to the model.
Body mass index is used an approximation to waist-hip
ratio, and TC/HDL ratio as a proxy for ApoB/ApoA1 ratio.
Use of these proxy measures will reduce the accuracy of
the model and waist-hip ratio and the ApoB/A1 ratio
should be used in preference, when available.
Individuals at high risk of CHD are often at high risk from
competing causes of death. Consequently, some individu-
als at high risk may die from another cause prior to a pre-
dicted CHD event. This could lead to overestimation of
risk from CHD in those at highest risk.
Our method takes a population mortality rate and preva-
lence rates for CVD and adjusts them using the mean val-
ues for risk factors in the given population. This is valid
provided the distribution of risk factor values is not heav-
ily skewed and the relationship between the risk factor
values and mortality rates obey the assumptions described
above.
5 Conclusion
This paper demonstrates how a comprehensive, mixed
odds model can be constructed using widely available
information and without access to training data sets. The
method could be useful in modeling a broad range of dis-
ease areas. Further research needs to be done to evaluate
the accuracy of the model in different population groups
using historical cohort data.
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